Sanofi's oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib has gained US Food and Drug Administration ...

which began in 2017 with the aim to clear out the backlog and streamline the ODD application process.” The pricing question There’s no doubt that rare diseases are an incredibly difficutl area ...

Despite challenges with elderly and critical patients, scenes dynamics and session duration promise to make therapy more ...